Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic cough
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-08-01
|
| Series: | World Allergy Organization Journal |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S193945512030106X |
| _version_ | 1818120159833882624 |
|---|---|
| author | David Muccino George Philip A.H. Morice S.S. Birring L. Mcgarvey P.V. Dicpinigaitis I.D. Pavord A.M. Tershakovec M.M. Kitt C. Assaid J.A. Smith |
| author_facet | David Muccino George Philip A.H. Morice S.S. Birring L. Mcgarvey P.V. Dicpinigaitis I.D. Pavord A.M. Tershakovec M.M. Kitt C. Assaid J.A. Smith |
| author_sort | David Muccino |
| collection | DOAJ |
| first_indexed | 2024-12-11T05:21:40Z |
| format | Article |
| id | doaj.art-9675d58a5c2d4aa6a7bda944be7a50c6 |
| institution | Directory Open Access Journal |
| issn | 1939-4551 |
| language | English |
| last_indexed | 2024-12-11T05:21:40Z |
| publishDate | 2020-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | World Allergy Organization Journal |
| spelling | doaj.art-9675d58a5c2d4aa6a7bda944be7a50c62022-12-22T01:19:42ZengElsevierWorld Allergy Organization Journal1939-45512020-08-01138100203Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic coughDavid Muccino0George Philip1A.H. Morice2S.S. Birring3L. Mcgarvey4P.V. Dicpinigaitis5I.D. Pavord6A.M. Tershakovec7M.M. Kitt8C. Assaid9J.A. Smith10Merck & Co., Inc., Kenilworth, United StatesMerck & Co., Inc., Kenilworth, United StatesHull York Medical School, Cottingham, United KingdomKing's College London, London, United KingdomQueen's University Belfast, Belfast, United KingdomAlbert Einstein College of Medicine, Bronx, United States; Montefiore Medical Center, Bronx, United StatesUniversity of Oxford, Oxford, United KingdomMerck & Co., Inc., Kenilworth, United StatesMerck & Co., Inc., Kenilworth, United StatesMerck & Co., Inc., Kenilworth, United StatesUniversity of Manchester, Manchester, United Kingdomhttp://www.sciencedirect.com/science/article/pii/S193945512030106X |
| spellingShingle | David Muccino George Philip A.H. Morice S.S. Birring L. Mcgarvey P.V. Dicpinigaitis I.D. Pavord A.M. Tershakovec M.M. Kitt C. Assaid J.A. Smith Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic cough World Allergy Organization Journal |
| title | Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic cough |
| title_full | Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic cough |
| title_fullStr | Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic cough |
| title_full_unstemmed | Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic cough |
| title_short | Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic cough |
| title_sort | rationale and design of two phase 3 randomized controlled trials cough 1 and cough 2 of gefapixant a p2x3 receptor antagonist in refractory and unexplained chronic cough |
| url | http://www.sciencedirect.com/science/article/pii/S193945512030106X |
| work_keys_str_mv | AT davidmuccino rationaleanddesignoftwophase3randomizedcontrolledtrialscough1andcough2ofgefapixantap2x3receptorantagonistinrefractoryandunexplainedchroniccough AT georgephilip rationaleanddesignoftwophase3randomizedcontrolledtrialscough1andcough2ofgefapixantap2x3receptorantagonistinrefractoryandunexplainedchroniccough AT ahmorice rationaleanddesignoftwophase3randomizedcontrolledtrialscough1andcough2ofgefapixantap2x3receptorantagonistinrefractoryandunexplainedchroniccough AT ssbirring rationaleanddesignoftwophase3randomizedcontrolledtrialscough1andcough2ofgefapixantap2x3receptorantagonistinrefractoryandunexplainedchroniccough AT lmcgarvey rationaleanddesignoftwophase3randomizedcontrolledtrialscough1andcough2ofgefapixantap2x3receptorantagonistinrefractoryandunexplainedchroniccough AT pvdicpinigaitis rationaleanddesignoftwophase3randomizedcontrolledtrialscough1andcough2ofgefapixantap2x3receptorantagonistinrefractoryandunexplainedchroniccough AT idpavord rationaleanddesignoftwophase3randomizedcontrolledtrialscough1andcough2ofgefapixantap2x3receptorantagonistinrefractoryandunexplainedchroniccough AT amtershakovec rationaleanddesignoftwophase3randomizedcontrolledtrialscough1andcough2ofgefapixantap2x3receptorantagonistinrefractoryandunexplainedchroniccough AT mmkitt rationaleanddesignoftwophase3randomizedcontrolledtrialscough1andcough2ofgefapixantap2x3receptorantagonistinrefractoryandunexplainedchroniccough AT cassaid rationaleanddesignoftwophase3randomizedcontrolledtrialscough1andcough2ofgefapixantap2x3receptorantagonistinrefractoryandunexplainedchroniccough AT jasmith rationaleanddesignoftwophase3randomizedcontrolledtrialscough1andcough2ofgefapixantap2x3receptorantagonistinrefractoryandunexplainedchroniccough |